Patents by Inventor Robert Rothlein

Robert Rothlein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rage fusion proteins and methods of use
    Patent number: 8877192
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: November 4, 2014
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Nucleic acid molecules encoding rage fusion proteins
    Patent number: 8344120
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: January 1, 2013
    Assignee: TransTech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20120171202
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 3, 2011
    Publication date: July 5, 2012
    Inventors: ADNAN M.M. MJALLI, YE EDWARD TIAN, JEFFREY C. WEBSTER, ROBERT ROTHLEIN
  • Rage Fusion Proteins, Formulations And Methods Of Use Thereof
    Publication number: 20110282035
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: June 13, 2011
    Publication date: November 17, 2011
    Inventors: Adnan M.M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster, Eric J. Benjamin
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20110244516
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: February 17, 2011
    Publication date: October 6, 2011
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Rage fusion proteins
    Patent number: 7981423
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: July 19, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Ye E. Tian, Jeffrey C. Webster, Robert Rothlein
  • RAGE fusion proteins, formulations, and methods of use thereof
    Patent number: 7981424
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: July 19, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert Rothlein, Ye Edward Tian, Jeffrey C. Webster, Eric J. Benjamin
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20110124102
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 7, 2011
    Publication date: May 26, 2011
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Immunoglobulin Fusion Proteins and Methods of Making
    Publication number: 20110110945
    Abstract: Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
    Type: Application
    Filed: October 6, 2010
    Publication date: May 12, 2011
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Rage fusion proteins
    Patent number: 7901688
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: March 8, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Aryl and heteroaryl compounds, compositions, and methods of use
    Patent number: 7544699
    Abstract: This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be useful for inhibiting the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: June 9, 2009
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Xiao-Chuan Guo, Daniel Peter Christen, Devi Reddy Gohimmukkula, Guoxiang Huang, Robert Rothlein, Sameer Tyagi, Tripura Yaramasu, Christopher Behme
  • Rage Fusion Proteins and Methods of Use
    Publication number: 20090060925
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: August 3, 2005
    Publication date: March 5, 2009
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein, David M. Stern, Ann Marie Schmidt, Shi Du Yan
  • Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith
    Publication number: 20090035302
    Abstract: Disclosed are RAGE antagonist compounds that have the ability to reverse pre-existing amyloidosis. Treatment with the RAGE antagonist compounds described herein may be used to reduce plaque size and improve cognition for subjects in the later stages of Alzheimer's disease. Additionally, the RAGE antagonists described herein may be used to reduce the onset of plaque formation and thereby prevent loss of cognition and other symptoms associated with Alzheimer's Disease and other diseases of amyloid deposition.
    Type: Application
    Filed: September 25, 2008
    Publication date: February 5, 2009
    Applicant: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Robert C. Andrews, Jane M. Shen, Robert Rothlein
  • Intercellular adhesion molecules and their binding ligands
    Publication number: 20090035321
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Application
    Filed: December 4, 2006
    Publication date: February 5, 2009
    Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
  • Rage Fusion Proteins And Methods Of Use
    Publication number: 20090004190
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: January 23, 2007
    Publication date: January 1, 2009
    Inventors: Adnan M.M. Mjalli, Jeffrey C. Webster, Robert Rothlein, Ye E. Tian
  • Immunoglobulin fusion proteins and methods of making
    Publication number: 20080199467
    Abstract: Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
    Type: Application
    Filed: February 11, 2008
    Publication date: August 21, 2008
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Functional derivatives of ICAM-1 with altered ability to bind LFA-1 or HRV
    Patent number: 7354588
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 8, 2008
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
  • Rage Fusion Proteins And Method Of Use
    Publication number: 20080075733
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: August 3, 2005
    Publication date: March 27, 2008
    Applicant: TRANSTECH PHARMA, INC.
    Inventors: Adnan Mjalli, Ye Tian, Jeffrey Webster, Robert Rothlein
  • RAGE fusion proteins, formulations, and methods of use thereof
    Publication number: 20080045455
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: April 25, 2007
    Publication date: February 21, 2008
    Inventors: Adnan Mjalli, Robert Rothlein, Ye Tian, Jeffrey Webster, Eric Benjamin
  • Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
    Publication number: 20070219239
    Abstract: The present application provides nitrogen-containing heterocycle derivatives that are antiviral compounds that may be useful in the treatment of a viral infection. Compounds of Formula (I) and pharmaceutical compositions comprising a compound of Formula (I) may be administered to a subject for antiviral therapy or prophylaxis.
    Type: Application
    Filed: February 9, 2007
    Publication date: September 20, 2007
    Inventors: Adnan Mjalli, Jeremy Cooper, Murty Arimilli, Robert Andrews, Robert Rothlein, Taleb AlTel